A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2004
10/14/2004	WO2004087658A1 Indolone-acetamide derivatives, processes for preparing them and their uses
10/14/2004	WO2004087657A1 Anti-obesity agent
10/14/2004	WO2004087654A2 Phospholipase c inhibitors for use in treating inflammatory disorders
10/14/2004	WO2004087652A2 Imidazotriazine compounds
10/14/2004	WO2004087651A2 Formulations for tyrosine kinase inhibitors
10/14/2004	WO2004087649A2 Benodiazepine spirohydantoin cgrp receptor antagonists
10/14/2004	WO2004087648A2 Stabilized phenytoin containing composition
10/14/2004	WO2004087646A2 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
10/14/2004	WO2004087641A1 Hydrazone derivative
10/14/2004	WO2004087259A2 Pharmaceutical composition effective in treatment of mechanical allodynia, screening method of potential compound as said pharmaceutical composition, abd inspection method of mechanical allodynia
10/14/2004	WO2004087245A1 Oxygen inhalation apparatus and method
10/14/2004	WO2004087212A2 Nitric oxide in treatment of inflammation
10/14/2004	WO2004087211A2 Inhibitors of phosphodiesterases in infertility
10/14/2004	WO2004087209A1 Preparation for sustaining therapeutically effective blood concentration of analgesic activity potentiator
10/14/2004	WO2004087203A2 Immunostimulatory nucleic acid oil-in-water formulations for topical application
10/14/2004	WO2004087202A2 Pharmaceutical composition comprising a macrolide immunomodulator
10/14/2004	WO2004087197A1 Drug production process corresponding carrier and use
10/14/2004	WO2004087190A1 Method for the treatment of prostate cancer
10/14/2004	WO2004087184A1 Isolation of the hepatoprotective agent acteoside from colerbrokea oppositifolia
10/14/2004	WO2004087176A1 A composition (rucd) for protecting and/or repairing dna from oxidative damages and a method thereof
10/14/2004	WO2004087175A1 Oral extended release compressed tablets of multiparticulates
10/14/2004	WO2004087174A1 Parenteral formulation of mycophenolic acid, a salt or prodrug thereof
10/14/2004	WO2004087173A2 Formulations for mediating inflammation and for reducing blood cholesterol
10/14/2004	WO2004087172A1 T-type calcium channel blockers
10/14/2004	WO2004087171A1 Methods for treating arthritic conditions
10/14/2004	WO2004087170A1 Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease
10/14/2004	WO2004087169A1 Antiviral combination of nevirapine and a further antiretroviral compound
10/14/2004	WO2004087168A1 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
10/14/2004	WO2004087167A2 Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
10/14/2004	WO2004087166A1 Use of carbamazepine derivatives for the treatment of agitation in dementia patients
10/14/2004	WO2004087165A1 Therapeutic agent for prostatic hypertrophy
10/14/2004	WO2004087164A1 8-nitro-tryptanthrin and other tryptanthrin derivatives used for the treatment of diseases caused by highly proliferating cells
10/14/2004	WO2004087163A2 Pharmacokinetics modifying chemotherapy
10/14/2004	WO2004087162A1 Uses of tryprostatin for the reversal of cancer drug resistance
10/14/2004	WO2004087161A1 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
10/14/2004	WO2004087160A1 Treatment of neurological conditions
10/14/2004	WO2004087158A2 Muscarinic m1 receptor agonists for pain management
10/14/2004	WO2004087157A2 Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease
10/14/2004	WO2004087154A1 Use of cuminum cyminum extract and piperine for potentiation of bioefficacy of anti infectives
10/14/2004	WO2004087153A2 Use of organic compounds for immunopotentiation
10/14/2004	WO2004087152A1 Dosage forms comprising ag013736
10/14/2004	WO2004087151A1 Medicinal composition
10/14/2004	WO2004087150A1 Drug composition
10/14/2004	WO2004087149A1 Medicinal composition
10/14/2004	WO2004087148A1 Remedy and/or preventive for lung diseases
10/14/2004	WO2004087147A1 Remedy and/or preventive for lung diseases
10/14/2004	WO2004087146A1 Processes for production of fine particle mixtures
10/14/2004	WO2004087144A1 Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases
10/14/2004	WO2004087143A1 Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials
10/14/2004	WO2004087141A1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases
10/14/2004	WO2004087140A1 Antiviral combination of a dipyridodiazepinone and a further antiretroviral compound
10/14/2004	WO2004087139A1 Antiviral combination of tipranavir and a further antiretroviral compound
10/14/2004	WO2004087138A1 Method for treating vascular hyperpermeable disease
10/14/2004	WO2004087136A1 Use of atii antagonist for the treatment or prevention of metabolic syndrome
10/14/2004	WO2004087135A1 Oral suspension of tegaserod
10/14/2004	WO2004087134A1 Use of the hydrochloride of the active ingredient base 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine combined with sumatriptan for the treatment of migraines
10/14/2004	WO2004087133A1 Crystalline n-formyl hydroxylamine compounds
10/14/2004	WO2004087132A2 Combination drug therapy for treating hypertension
10/14/2004	WO2004087131A1 Antitussives
10/14/2004	WO2004087130A1 Hepatoprotective pharmaceutical composition comprising a mixture of coumarinolignoids and process for preparation thereof
10/14/2004	WO2004087129A1 Composition for preventing or treating allergic disease using black rice extract and its therapeutic use
10/14/2004	WO2004087128A1 Methyl-β-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer
10/14/2004	WO2004087127A1 Synergistic hepatoprotective composition and a method thereof
10/14/2004	WO2004087126A1 Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
10/14/2004	WO2004087124A1 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders
10/14/2004	WO2004087123A1 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
10/14/2004	WO2004087122A1 (+)-1-bisabolone isolated from cymbopogon flexosus and antibacterial activity thereof
10/14/2004	WO2004087121A2 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
10/14/2004	WO2004087120A2 Use of quinazoline derivatives with src kinase inhibitory activity for the treatment of hypertension
10/14/2004	WO2004087119A2 Compositions containing superoxide dismutase and a selected et 5-lipoxygenase inhibitor and uses thereof
10/14/2004	WO2004087118A2 Synergistic combinations of macrolide t-cell modulator or inmunosuppressant and a retinoid
10/14/2004	WO2004087117A2 Use of cyclic acetals/ketals for improved penetration of active substances into cells and organs
10/14/2004	WO2004087116A2 Drug combination for motor dysfunction in parkinson's disease
10/14/2004	WO2004087113A1 Pharmaceutical compositions for colon specific delivery
10/14/2004	WO2004087112A1 Manufacturing method and formulation for bitter taste masked oral dosage form of clarithromycin
10/14/2004	WO2004087111A1 Oral taste masked pharmaceutical compositions
10/14/2004	WO2004087109A1 Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
10/14/2004	WO2004087108A1 Taste-masking vehicle for coated oxazolidinone particles
10/14/2004	WO2004087104A1 Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
10/14/2004	WO2004087103A1 Ophthalmic drug delivery system using polymer micell
10/14/2004	WO2004087101A2 Oral formulations of cladribine
10/14/2004	WO2004087100A2 Cladribine formulations for improved oral and transmucosal delivery
10/14/2004	WO2004087098A2 Preserved ophthalmic compositions
10/14/2004	WO2004087097A2 Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
10/14/2004	WO2004087096A1 Pharmaceutical compositions having reduced bitter taste
10/14/2004	WO2004087095A2 Osmotic controlled release device containing zafirlukast and an h1-antagonist
10/14/2004	WO2004087093A1 A topical agent containing niacin for application to the skin prior to luminous treatment
10/14/2004	WO2004087085A1 Methods of promoting hair growth
10/14/2004	WO2004087076A2 Methods for inhibiting adipogenesis and for treating type 2 diabetes
10/14/2004	WO2004087075A2 Compositions and methods for treating cancer
10/14/2004	WO2004087073A2 Treatment of demyelinating conditions
10/14/2004	WO2004087072A2 Topical l-carnitine compositions
10/14/2004	WO2004087071A2 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection
10/14/2004	WO2004087066A2 Hif-1 inhibitors
10/14/2004	WO2004087061A2 Tubulin binding agents and corresponding prodrug constructs
10/14/2004	WO2004087056A2 BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
10/14/2004	WO2004087055A2 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation
10/14/2004	WO2004087053A2 Dipeptidyl peptidase inhibitors
10/14/2004	WO2004087051A2 Ophthalmic compositions for treating ocular hypertension
10/14/2004	WO2004087048A2 Benzamide modulators of metabotropic glutamate receptors

1 ... 4923 4924 4925 4926 4927 4928 4929 4930 4931 4932 4933 4934 4935 4936 4937 4938 4939 4940 4941 4942 4943 ... 7860